Trial Profile
A Single Arm Study of 6-Months Neoadjuvant Apalutamide Prior to Radical Prostatectomy in Intermediate Risk Patients to Reduce the Frequency of Pathologic Features That Drive Post-Operative Radiation Therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Apr 2023
Price :
$35
*
At a glance
- Drugs Apalutamide (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 28 Mar 2023 Planned End Date changed from 28 Feb 2023 to 30 Jul 2024.
- 28 Mar 2023 Planned primary completion date changed from 28 Feb 2023 to 30 Jul 2024.
- 13 Sep 2021 Status changed from active, no longer recruiting to completed.